AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05556421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: uterocervical angle
Description: uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
Study NCT05124509 — intervention group
Intervention type: BIOLOGICAL
Intervention: Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)
Description: Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
Study NCT05124509 — intervention group
Intervention type: BIOLOGICAL
Intervention: Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
Description: Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
Study NCT04804631 — intervention group
Intervention type: DEVICE
Intervention: Enteral feeding tubes
Description: Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
Study NCT05963217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-2001
Description: Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion.
Study NCT05963217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Study NCT05963217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Study NCT04766580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo and nocebo effect
Description: The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
Study NCT04766580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and nocebo effect
Description: The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
Study NCT06352281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
Study NCT06066554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puva (psoralin and uva )
Description: Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
Study NCT04356664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: One or two intramuscular injections of Decapeptyl 3 mg
Study NCT04970888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
Study NCT04970888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
Study NCT04970888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
Study NCT04970888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
Study NCT05637398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
Study NCT05769881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided subcostal transversus abdominis plane block
Description: After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
Study NCT05769881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound site local anesthetic infiltration
Description: After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
Study NCT05639153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR30303
Description: DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
Study NCT06306963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Emptying
Description: Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours.~To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine.
Study NCT05426902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLE@Duke
Description: SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
Study NCT06408532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: The participants in this group will be switched to IDegLira once daily injection therapy.
Study NCT06408532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin
Description: The participants in this group will be have optimized premixed insulin regimen.
Study NCT06699355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral administration
Study NCT06034470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06034470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study NCT06034470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06034470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT05024175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Disease assessments
Description: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
Study NCT06034470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06034470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT06034470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC
Study NCT05024175 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: Tumor Biopsy per protocol
Study NCT05024175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood Test per protocol
Study NCT06034470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT06034470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT06034470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivekimab Sunirine
Description: Given IV
Study NCT06699355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral administration
Study NCT05744154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit & feedback with educational outreach and facilitation
Description: As in arm descriptions
Study NCT05744154 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simple audit & feedback (usual practice)
Description: As in arm descriptions
Study NCT05243862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyPEPI1018
Description: PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
Study NCT05243862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
Study NCT06369376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New nerve conduction protocol
Description: We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
Study NCT06698796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazukibart
Description: anti-interferon beta therapy
Study NCT06698341 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
Study NCT06489158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detect VOCs in exhaled gas
Description: The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
Study NCT04975919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT04975919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06699173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat ped
Description: The hot ped was used during ricig cystoscopy
Study NCT06698835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turnip Consumption
Description: Turnip Consumption and Qigong Exercise with educational Program about loss of weight
Study NCT03582085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin Vaccine
Description: Experimental
Study NCT03582085 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Placebo
Study NCT06114069 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported maxillary fixed prosthesis
Description: Maxillary fixed prosthesis according to all on four or all on six concept
Study NCT05490732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture
Study NCT06404320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA program - MoveU.HappyU
Description: Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week.
Study NCT06252961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole 3 days
Description: Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
Study NCT06252961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole 5 days
Description: Levamisole for 5 days (2,5 mg/kg)
Study NCT06252961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days
Study NCT05723835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
Study NCT06497777 — intervention group
Intervention type: GENETIC
Intervention: MicroRNA (mir-642b-3p)
Description: A circulating microRNA in the blood of pancreatic cancer patients.
Study NCT04451564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness oriented recovery enhancement
Description: 8- week psychological program based on mindfulness techniques
Study NCT05659719 — intervention group
Intervention type: OTHER
Intervention: Recifercept
Description: Patients received recifercept intervention in the phase 2 clinical trial
Study NCT04554966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) infusion
Study NCT04554966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous (SC) injection
Study NCT04554966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: Intravenous (IV) infusion
Study NCT05720858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
Study NCT05210803 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: All subjects that previously received RGX-314 in a parent study
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
Study NCT05104892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05104892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT04811391 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
Study NCT05552950 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BioBlock® antiviral nasal spray
Description: SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
Study NCT05552950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioBlock® antiviral nasal spray
Description: SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
Study NCT05745350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Plinabulin plus Etoposide and Platinum
Description: Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
Study NCT04893967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back
Study NCT04893967 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back
Study NCT04235049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir/pibrentasvir
Description: Treatment for HCV Infection
Study NCT04857242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apnea test, alveolar recruitment
Description: Alveolar recruitment following the phase of apnea testing
Study NCT05292911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT05292911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol Hydrochloride
Description: Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine Bitartrate
Description: Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate
Description: Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
Study NCT05997732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.